Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease

Journal of Proteomics

Volumn 116, Issue , 2015, Pages 24-33

  Yuan, Wei ^a   Sanda, Miloslav ^a   Wu, Jing ^a   Koomen, John ^b   Goldman, Radoslav ^a,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cirrhosis; Glycosylation; HCV; Hepatocellular carcinoma (HCC); Immunoglobulin; LC MS MRM

Indexed keywords

GLYCAN DERIVATIVE; HYDRONIUM ION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN A2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; IMMUNOGLOBULIN SUBCLASS; STABLE ISOTOPE; CANCER ANTIBODY; GALACTOSE;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; BIOLOGICAL MONITORING; CALIBRATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FUCOSYLATION; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PURIFICATION; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; BLOOD; CLASSIFICATION; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED;

HEPATITIS C VIRUS;

ANTIBODIES, NEOPLASM; CARCINOMA, HEPATOCELLULAR; FEMALE; GALACTOSE; GLYCOSYLATION; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SPECTROMETRY; MIDDLE AGED;

EID: 84921535104     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.12.020     Document Type: Article

References (50)

1. El-Serag H.B., Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 2014, 60:1767-1775.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
4. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
5. Meulenbroek A.J. Human IgG subclasses: useful diagnostic markers for immunocompetence 2008, Sanquin, Amsterdam.
6. Watt K., Uhanova J., Gong Y., Kaita K., Doucette K., Pettigrew N., et al. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat 2004, 11:251-256.
7. Musset L., Lunel F., Cacoub P., Mannant P.R., Silvain C., Lacombe C., et al. Increased serum immunoglobulin G1 levels in hepatitis C virus infection. Hepatology 1995, 21:1755-1757.
8. Pontisso P., Quarta S., Caberlotto C., Beneduce L., Marino M., Bernardinello E., et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006, 119:735-740.
9. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008, 14:25-27.
10. Ball J.K., Tarr A.W., McKeating J.A. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 2014, 105:100-111.
11. Kong L., Giang E., Nieusma T., Kadam R.U., Cogburn K.E., Hua Y., et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013, 342:1090-1094.
12. Spengler U., Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007, 112:141-155.
13. Nattermann J., Schneiders A.M., Leifeld L., Langhans B., Schulz M., Inchauspé G., et al. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). J Hepatol 2005, 42:499-504.
14. Balagopal A., Philp F.H., Astemborski J., Block T.M., Mehta A., Long R., et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008, 135:226-233.
15. Mehta A.S., Long R.E., Comunale M.A., Wang M., Rodemich L., Krakover J., et al. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008, 82:1259-1270.
16. Klein A., Michalski J.C., Morelle W. Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, is it all about immunoglobulins?. Proteomics Clin Appl 2010, 4:372-378.
17. Vanderschaeghe D., Laroy W., Sablon E., Halfon P., Van Hecke A., Delanghe J., et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009, 8:986-994.
18. Zauner G., Selman M.H., Bondt A., Rombouts Y., Blank D., Deelder A.M., et al. Glycoproteomic analysis of antibodies. Mol Cell Proteomics 2013, 12:856-865.
19. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007, 25:21-50.
20. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003, 325:979-989.
21. Rudd P.M., Elliott T., Cresswell P., Wilson I.A., Dwek R.A. Glycosylation and the immune system. Science 2001, 291:2370-2376.
22. Klein A., Carre Y., Louvet A., Michalski J.C., Morelle W. Immunoglobulins are the major glycoproteins involved in the modifications of total serum N-glycome in cirrhotic patients. Proteomics Clin Appl 2010, 4:379-393.
23. Shade K.T., Anthony R. Antibody glycosylation and inflammation. Antibodies 2013, 2:392-414.
24. Bekesova S., Kosti O., Chandler K.B., Wu J., Madej H.L., Brown K.C., et al. N-glycans in liver-secreted and immunoglobulin-derived protein fractions. J Proteomics 2012, 75:2216-2224.
25. Tissandié E., Morelle W., Berthelot L., Vrtovsnik F., Daugas E., Walker F., et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 2011, 80:1352-1363.
26. Balbin M., Grubb A., de Lange G.G., Grubb R. DNA sequences specific for Caucasian G3m(b) and (g) allotypes: allotyping at the genomic level. Immunogenetics 1994, 39:187-193.
27. Sanda M., Pompach P., Brnakova Z., Wu J., Makambi K., Goldman R. Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics 2013, 12:1294-1305.
28. Remily-Wood E.R., Benson K., Baz R.C., Chen Y.A., Hussein M., Hartley-Brown M.A., et al. Quantification of peptides from immunoglobulin constant and variable regions by liquid chromatography-multiple reaction monitoring mass spectrometry for assessment of multiple myeloma patients. Proteomics Clin Appl 2014, 8:783-795.
29. Remily-Wood E.R., Koomen J.M. Evaluation of protein quantification using standard peptides containing single conservative amino acid replacements. J Mass Spectrom 2012, 47:188-194.
30. Hagman C., Ricke D., Ewert S., Bek S., Falchetto R., Bitsch F. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal Chem 2008, 80:1290-1296.
31. Stadlmann J., Pabst M., Kolarich D., Kunert R., Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008, 8:2858-2871.
32. Selman M.H., Derks R.J., Bondt A., Palmblad M., Schoenmaker B., Koeleman C.A., et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J Proteomics 2012, 75:1318-1329.
33. Ackerman M.E., Crispin M., Yu X., Baruah K., Boesch A.W., Harvey D.J., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 2013, 123:2183-2192.
34. Sondermann P., Pincetic A., Maamary J., Lammens K., Ravetch J.V. General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci U S A 2013, 110:9868-9872.
35. Barnidge D.R., Dratz E.A., Martin T., Bonilla L.E., Moran L.B., Lindall A. Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. Anal Chem 2003, 75:445-451.
36. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-588.
37. Sanda M., Pompach P., Benicky J., Goldman R. LC-MS3 quantification of O-glycopeptides in human serum. Electrophoresis 2013, 34:2342-2349.
38. Toyama A., Nakagawa H., Matsuda K., Sato T.A., Nakamura Y., Ueda K. Quantitative structural characterization of local N-glycan microheterogeneity in therapeutic antibodies by energy-resolved oxonium ion monitoring. Anal Chem 2012, 84:9655-9662.
39. Hong Q., Lebrilla C.B., Miyamoto S., Ruhaak L.R. Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem 2013, 85:8585-8593.
40. Einarsdottir H.K., Selman M.H., Kapur R., Scherjon S., Koeleman C.A., Deelder A.M., et al. Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J 2013, 30:147-157.
41. Ladwig P.M., Barnidge D.R., Snyder M.R., Katzmann J.A., Murray D.L. Quantification of serum IgG subclasses by use of subclass-specific tryptic peptides and liquid chromatography-tandem mass spectrometry. Clin Chem 2014, 60:1080-1088.
42. Lefranc M.P., Lefranc G. Human Gm, Km, and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism. Methods Mol Biol 2012, 882:635-680.
43. Anthony R.M., Ravetch J.V. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010, 30(Suppl. 1):S9-S14.
44. Parekh R.B., Dwek R.A., Sutton B.J., Fernandes D.L., Leung A., Stanworth D., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316:452-457.
45. Tomana M., Schrohenloher R.E., Koopman W.J., Alarcon G.S., Paul W.A. Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 1988, 31:333-338.
46. Malhotra R., Wormald M.R., Rudd P.M., Fischer P.B., Dwek R.A., Sim R.B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995, 1:237-243.
47. Karsten C.M., Pandey M.K., Figge J., Kilchenstein R., Taylor P.R., Rosas M., et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012, 18:1401-1406.
48. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740.
49. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
50. Abes R., Teillaud L.-L. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010, 3:146-157.